Complement Regulation to Undo Systemic Harm in Preeclampsia
Status:
Recruiting
Trial end date:
2024-03-13
Target enrollment:
Participant gender:
Summary
This is a Phase II, single arm, open-label study to determine if treatment with eculizumab
prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30
weeks gestation.